Brain Cancer Treatment in India
Get Brain Cancer Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Brain Cancer Treatment in UAE
Brain Cancer Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Brain cancer treatment encompasses a spectrum of advanced interventions — including neurosurgical resection, stereotactic radiosurgery, targeted molecular therapy, and immunotherapy — tailored to tumor grade, histology, and patient performance status. For primary brain tumors such as glioblastoma multiforme (GBM), overall survival outcomes with modern multimodal protocols have improved significantly, with five-year survival rates reaching 5–10% for GBM and exceeding 85–90% for low-grade gliomas and meningiomas when treated at high-volume centers. GAF Healthcare connects international patients with JCI- and NABH-accredited neurosurgical centers in India and JCI- and DHA-licensed institutions in Dubai and Abu Dhabi, offering world-class neuro-oncology expertise at a fraction of Western costs, with full end-to-end medical travel coordination.
Hospital Stay: 7–21 days (varies by procedure: craniotomy averages 10–14 days; radiosurgery may require only 1–3 days inpatient) • Total Stay in Country (Fit-to-Fly): 4–8 weeks post-surgery (radiosurgery patients may be fit to fly in 1–2 weeks pending neurological stability and oncologist clearance) • Success Rate: Gross total resection achieved in 70–85% of operable cases; 5-year survival: 85–92% (low-grade glioma/meningioma), 5–10% (GBM with Stupp protocol)
What Is It?
Brain cancer refers to malignant neoplasms originating within the central nervous system (primary brain tumors) or metastasizing to the brain from systemic cancers such as lung, breast, or melanoma (secondary/metastatic brain tumors). Primary brain tumors are classified by the WHO 2021 CNS tumor classification, which integrates histological morphology with molecular markers — including IDH1/IDH2 mutation status, MGMT promoter methylation, 1p/19q codeletion, TERT promoter mutations, and EGFR amplification — to define tumor grade and predict treatment response. Glioblastoma multiforme (GBM, WHO Grade IV) is the most aggressive primary brain tumor, with a median survival of 14–16 months under standard Stupp protocol (concurrent temozolomide chemotherapy with radiotherapy followed by adjuvant temozolomide cycles). Lower-grade gliomas (WHO Grade II–III), meningiomas, pituitary adenomas, and medulloblastomas carry substantially better prognoses and often respond well to surgical resection alone or combined modality therapy.
Physiologically, brain tumors exert their damage through mass effect — compressing and displacing critical neural structures — and through peritumoral edema, elevated intracranial pressure (ICP), disruption of the blood-brain barrier, and direct infiltration of eloquent cortex governing motor, language, memory, and autonomic functions. Patients may present with new-onset seizures, progressive focal neurological deficits (hemiparesis, aphasia, visual field defects), personality changes, headache with features of raised ICP (worse in the morning, associated with nausea), or cognitive decline. Prompt and accurate diagnosis followed by multidisciplinary tumor board evaluation is the cornerstone of optimal outcomes.
The current standard of care for resectable brain tumors involves maximal safe surgical resection guided by intraoperative neurophysiological monitoring (IONM), 5-aminolevulinic acid (5-ALA) fluorescence-guided surgery, or intraoperative MRI (iMRI), followed by adjuvant radiotherapy and chemotherapy as dictated by molecular profiling. Unresectable or eloquently located tumors may be treated with stereotactic radiosurgery (Gamma Knife, CyberKnife, or Novalis TX linear accelerator), laser interstitial thermal therapy (LITT), or emerging investigational therapies including tumor treating fields (Optune device), bevacizumab (anti-VEGF), and immune checkpoint inhibitors. All treatment decisions are made by a dedicated neuro-oncology multidisciplinary team (MDT) comprising neurosurgeons, radiation oncologists, medical oncologists, neuroradiologists, and neuropathologists.
Candidates
• **Confirmed or suspected brain tumor on neuroimaging**: Patients with MRI brain with gadolinium contrast demonstrating a space-occupying lesion requiring histopathological diagnosis or definitive treatment.
• **Newly diagnosed or recurrent primary brain tumors**: Including glioblastoma (GBM), anaplastic astrocytoma, oligodendroglioma, meningioma (Grade I–III), medulloblastoma, ependymoma, or PCNSL (primary CNS lymphoma).
• **Resectable tumors in non-eloquent cortex**: Candidates for craniotomy with awake brain surgery when lesions are near speech or motor cortex.
• **Unresectable or deep-seated tumors**: Suitable for stereotactic biopsy, Gamma Knife radiosurgery, or CyberKnife SBRT (e.g., thalamic, brainstem, or basal ganglia tumors).
• **Brain metastases (1–4 lesions)**: Candidates for stereotactic radiosurgery (SRS) ± whole-brain radiotherapy (WBRT) or surgical resection if single large symptomatic metastasis.
• **MGMT-methylated GBM patients**: Particularly benefit from temozolomide chemotherapy; molecular testing mandatory prior to treatment planning.
• **Required Pre-Treatment Diagnostics**:
- MRI brain with and without gadolinium contrast (standard 3T; preferably 7T if available)
- MR spectroscopy, MR perfusion, and functional MRI (fMRI) for eloquent cortex mapping
- PET-CT with FDG or amino acid tracers (18F-FET or 11C-MET) for metabolic grading and recurrence differentiation
- Complete blood panel: CBC, CMP, coagulation profile (PT/INR/aPTT), LFT, RFT
- Molecular/genomic profiling: IDH1/2 mutation, MGMT promoter methylation, 1p/19q codeletion, EGFR amplification, BRAF V600E, H3K27M (for midline tumors)
- Neuropsychological assessment and Karnofsky Performance Status (KPS) scoring
- Electroencephalogram (EEG) if seizure history present
- Ophthalmology review for visual pathway tumors
- Lumbar puncture and CSF cytology for suspected leptomeningeal disease or PCNSL
• **Contraindications and Cautions**:
- KPS < 40 or WHO Performance Status > 3 (poor surgical candidacy; palliative approach preferred)
- Active uncontrolled systemic infection or coagulopathy uncorrectable pre-operatively
- Brainstem or bilateral thalamic involvement (limits surgical candidacy; radiosurgery evaluated)
- Prior maximum-dose radiotherapy to the same field (re-irradiation risk assessed case-by-case)
- Severe cardiopulmonary comorbidity precluding general anesthesia (anesthesia risk stratification required)
- Diffuse leptomeningeal dissemination with poor systemic performance (systemic therapy or palliative care pathway)
Procedure
**1. Craniotomy with Maximal Safe Resection (Open Surgery)**
The gold standard for most resectable supratentorial and posterior fossa tumors. Performed under general anesthesia with neuronavigation (Brainlab or Medtronic StealthStation) for real-time 3D intraoperative guidance. Key adjuncts include:
• **5-ALA (5-aminolevulinic acid) fluorescence-guided surgery**: Oral 5-ALA administered 3–4 hours pre-op causes selective accumulation of protoporphyrin IX in malignant glioma cells, which fluoresce pink under blue-violet light, enabling the surgeon to distinguish tumor from normal brain and achieve higher rates of gross total resection (GTR).
• **Intraoperative MRI (iMRI)**: Real-time 1.5T or 3T MRI suite integrated into the operating room allows the surgeon to identify residual enhancing tumor during the same operative session, improving GTR rates from ~60% to >80%.
• **Intraoperative Neurophysiological Monitoring (IONM)**: Continuous motor evoked potentials (MEPs), somatosensory evoked potentials (SSEPs), and direct cortical stimulation mapping protect eloquent cortex and corticospinal tracts during resection.
• **Awake Craniotomy with Cortical Mapping**: For tumors within or adjacent to speech (Broca's/Wernicke's), motor, or sensory cortex. The patient is kept awake during a critical phase for real-time language and motor testing, allowing aggressive resection while preserving neurological function.
• **Carmustine (BCNU) Wafers (Gliadel)**: Biodegradable polymer wafers impregnated with carmustine chemotherapy placed directly into the tumor resection cavity at the time of surgery, providing sustained local chemotherapy delivery for GBM.
**2. Stereotactic Radiosurgery (SRS) — Gamma Knife, CyberKnife, Novalis TX**
High-precision, non-invasive delivery of ablative radiation doses in 1–5 fractions to a sharply defined target volume with sub-millimeter accuracy, sparing surrounding normal brain. Indicated for:
• Brain metastases (1–4 lesions, each < 3 cm)
• Residual or recurrent meningioma, acoustic neuroma (vestibular schwannoma), pituitary adenoma
• Deep-seated or eloquently located gliomas not amenable to open surgery
• Adjuvant boost after surgical resection cavity
Gamma Knife Icon (frameless) and CyberKnife (robotic linear accelerator) are available at leading centers in both India and the UAE.
**3. Conventional Radiotherapy and Proton Beam Therapy**
• **External Beam Radiotherapy (EBRT)** with IMRT (Intensity-Modulated Radiation Therapy) or VMAT (Volumetric Modulated Arc Therapy): Standard adjuvant treatment post-resection for GBM (60 Gy in 30 fractions) and high-grade gliomas.
• **Proton Beam Therapy (PBT)**: Available at select centers in India (Apollo Proton Cancer Centre, Chennai) and the UAE (Burjeel Proton Therapy Centre, Abu Dhabi). The Bragg peak physics of protons reduces exit dose to normal brain, particularly beneficial for pediatric brain tumors, chordomas, skull base tumors, and tumors near the optic apparatus.
**4. Laser Interstitial Thermal Therapy (LITT)**
Minimally invasive stereotactic neurosurgical technique in which a laser catheter is placed into the tumor under MRI guidance. Real-time MR thermometry monitors heat delivery, ablating tumor tissue with minimal open surgery. Ideal for deep-seated, small-volume recurrent GBM or radiation necrosis.
**5. Chemotherapy Protocols**
• **Stupp Protocol (GBM standard of care)**: Concurrent temozolomide (75 mg/m² daily) with radiotherapy, followed by 6 cycles of adjuvant temozolomide (150–200 mg/m²/day, 5/28 days). MGMT promoter methylation predicts superior benefit.
• **PCV Chemotherapy**: Procarbazine + CCNU (lomustine) + vincristine for 1p/19q co-deleted oligodendrogliomas (WHO Grade II–III).
• **Bevacizumab (Avastin)**: Anti-VEGF monoclonal antibody for recurrent GBM; reduces tumor-associated edema and radiographic response.
• **Lomustine monotherapy**: For recurrent GBM in bevacizumab-naive patients.
**6. Targeted Therapy and Immunotherapy (Emerging/Investigational)**
• **IDH inhibitors**: Enasidenib (IDH2), ivosidenib (IDH1) — approved for IDH-mutant astrocytomas in select regulatory jurisdictions; vorasidenib (dual IDH1/2 inhibitor) showing promising Phase III data.
• **BRAF/MEK inhibitors**: Dabrafenib + trametinib for BRAF V600E-mutant gliomas (pediatric high-grade glioma, pleomorphic xanthoastrocytoma).
• **Tumor Treating Fields (TTFields / Optune)**: Wearable device delivering low-intensity alternating electric fields (200 kHz) continuously to disrupt glioma cell mitosis; approved by FDA for newly diagnosed and recurrent GBM, extending median OS to 20.9 months in combination with temozolomide (EF-14 trial).
• **CAR-T cell therapy and checkpoint inhibitors (pembrolizumab, nivolumab)**: Active clinical trial programs at leading centers; not yet standard of care for GBM but available on protocol.
**7. Endoscopic Neurosurgery**
Minimally invasive neuroendoscopic approaches for intraventricular tumors (colloid cysts, ependymomas), pituitary adenomas (transsphenoidal endoscopic approach), and third ventricular tumors with concurrent endoscopic third ventriculostomy (ETV) for associated obstructive hydrocephalus.
Cost of Brain Cancer Treatment: India vs. UAE
Brain cancer treatment costs vary substantially depending on tumor type and grade, the surgical approach selected, whether adjuvant radiotherapy and chemotherapy are administered in-country, and the tier of hospital facility chosen. The following estimates cover the primary surgical or radiosurgical intervention plus standard hospital stay and medications, exclusive of multi-cycle chemotherapy, proton beam therapy, or extended rehabilitation, which are priced separately. India consistently offers costs 50–65% lower than the UAE for equivalent oncology expertise at JCI-accredited institutions, while the UAE provides premium facility standards, proximity for Gulf and European travelers, and a familiar international environment.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $6,000 – $25,000 | ~56% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $15,000 – $55,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
**Phase 1 — Pre-Arrival & Remote Evaluation (2–4 weeks before travel)**
• GAF Healthcare coordinates submission of all existing imaging (MRI DICOM files, PET-CT), histopathology reports, molecular panel results, and clinical records to the designated neuro-oncology MDT at the chosen hospital.
• Neuro-oncologist and neurosurgeon conduct a remote teleconsultation (video call) to review the case, determine operability, define the proposed treatment strategy, and issue a formal Treatment Plan & Cost Estimate.
• Pre-surgical anaesthesia risk assessment form completed; additional investigations (cardiac ECHO, pulmonary function tests) requested if indicated by comorbidities.
• GAF Healthcare initiates e-Medical Visa application (India) or entry visa facilitation (UAE) — see Logistics section.
**Phase 2 — Arrival & Pre-Operative Work-Up (Days 1–3 in country)**
• Airport transfer by GAF-coordinated private vehicle to partner hospital or accommodation.
• In-patient admission; dedicated patient coordinator and language interpreter assigned.
• Repeat high-resolution MRI brain (3T with gadolinium, fMRI, DTI tractography) at the treating hospital for neuronavigation planning.
• Full pre-operative blood panel, anaesthesia assessment, and neurosurgery consent process.
• MDT tumor board presentation and final surgical/treatment plan confirmation.
• Corticosteroids (dexamethasone) initiated to reduce peritumoral edema prior to surgery; anti-epileptic drug (AED) prophylaxis commenced if indicated.
**Phase 3 — Surgical or Primary Treatment (Days 3–5)**
• **Craniotomy**: Performed under general anaesthesia (or awake for eloquent cortex tumors); duration 4–10 hours depending on tumor size and location. Intraoperative 5-ALA fluorescence and/or iMRI utilized. IONM continuous throughout.
• **Stereotactic Radiosurgery**: Outpatient or 1-night admission; treatment session typically 30–90 minutes on the Gamma Knife or CyberKnife unit.
• **Stereotactic Biopsy**: 1–2 hour minimally invasive procedure under local or general anaesthesia for deep-seated or eloquently located tumors requiring tissue diagnosis.
**Phase 4 — Immediate Post-Operative Recovery (Days 5–14 for craniotomy)**
• ICU or neurosurgical HDU monitoring for 24–72 hours post-craniotomy: neurological observations, ICP monitoring if indicated, wound care.
• MRI brain performed within 24–72 hours post-operatively to assess extent of resection and rule out surgical complications.
• Tissue specimen sent for comprehensive neuropathology and molecular profiling (results in 7–14 business days from NABL/CAP-accredited lab).
• Physiotherapy commenced from Day 2 post-op: mobilization, swallowing assessment if posterior fossa surgery, speech therapy if indicated.
• Corticosteroid taper commenced; anti-epileptic management optimized.
• Sutures/staples removed on Day 7–10; wound assessed.
• Discharge from hospital when neurologically stable: typically Day 10–14 post-craniotomy.
**Phase 5 — In-Country Recovery & Adjuvant Treatment Planning (Weeks 3–8)**
• Patient recovers in GAF-arranged serviced accommodation; daily nursing visits or outpatient clinic check-ins as required.
• Molecular pathology results reviewed at MDT; decision on adjuvant radiotherapy and/or chemotherapy protocol made and communicated to patient and home oncologist.
• If adjuvant radiotherapy is to begin in the treatment country: simulation CT (radiation planning), mask fabrication, treatment planning, and initiation of a 6-week (30-fraction) radiotherapy course.
• Neuropsychological rehabilitation and occupational therapy sessions as needed.
• Pre-discharge neurosurgical review, post-op MRI review, and formal oncology hand-over report prepared for the patient's home oncology team.
**Phase 6 — Fit-to-Fly Clearance & Departure (Week 4–8)**
• Fitness-to-fly assessment by the treating neurosurgeon and oncologist.
• Craniotomy patients: generally fit for long-haul international flight at 4–6 weeks if neurologically stable, wound healed, no active VTE, and ICP normalised. Radiosurgery patients: typically fit to fly within 1–2 weeks.
• GAF Healthcare arranges medical escort if required, wheelchair assistance, in-flight medication and documentation pack.
• Comprehensive medical discharge summary, operative notes, pathology and molecular reports, radiotherapy dosimetry records, and follow-up MRI schedule provided in both English and, where requested, translated into the patient's home language.
**Recovery Milestones:**
• Wound healing: 2–3 weeks
• Return of baseline neurological function (if no permanent deficit): 4–12 weeks
• Fatigue improvement post-radiotherapy: 6–12 weeks after completing RT
• First follow-up MRI (surveillance for pseudoprogression vs. true progression): 4–6 weeks post-completion of chemoradiotherapy
• Subsequent MRI surveillance: every 2–3 months for first 2 years, then every 3–6 months
Risks & Considerations
Brain cancer treatment carries procedure-specific and disease-specific risks that must be understood by every patient prior to proceeding. Surgical risks of craniotomy include intraoperative and postoperative intracranial hemorrhage (1–3%), wound infection or meningitis (1–2%), perioperative cerebral edema and neurological deterioration, new permanent neurological deficits (motor weakness, aphasia, visual field loss) in 3–15% of cases depending on tumor eloquence, deep vein thrombosis (DVT) and pulmonary embolism (elevated in neuro-oncology patients due to hypercoagulability), seizures, and cerebrospinal fluid leak (0.5–2%). General anaesthesia carries standard risks of pulmonary, cardiac, and thromboembolic complications, heightened by steroid-induced hyperglycaemia and immunosuppression. Stereotactic radiosurgery risks include radiation necrosis (clinically symptomatic in 5–15% of cases within 6–18 months), perilesional edema requiring steroid management, and — particularly with WBRT — cognitive decline, fatigue, and alopecia. Temozolomide chemotherapy risks include myelosuppression (neutropenia, thrombocytopenia), hepatotoxicity, nausea, opportunistic infection (Pneumocystis jirovecii pneumonia prophylaxis with trimethoprim-sulfamethoxazole is standard), and rare secondary malignancy with prolonged use. Bevacizumab carries risks of hypertension, impaired wound healing, thromboembolic events, and gastrointestinal perforation. Tumor Treating Fields (Optune) may cause scalp skin irritation and social challenges related to device wearability. Patients must also understand that for GBM, despite all interventions, median overall survival remains 14–20 months with current standard-of-care regimens; establishing realistic expectations with clear palliative care integration is an ethical imperative in neuro-oncology. All risks are discussed in detail during the pre-operative MDT consultation and documented in the informed consent process at partner hospitals coordinated by GAF Healthcare.
Top Hospitals for Brain Cancer Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Tata Memorial Hospital
Mumbai, India
Top Doctors for Brain Cancer Treatment
Internationally trained specialists in Cancer Care. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Svati Bansal
MBBS, MS (Ophthalmology), Fellowship in Oculoplasty and Ocular Oncology, Fellowship in Neuro-Ophthalmology, Training in Facial Reconstructive Surgery
Oculoplasty, Neuro-Ophthalmology & Ocular Oncology Specialist
Fortis Memorial Research Institute, Gurgaon, India
20+ Yearsof experience
Dr. Svati Bansal is one of India's most comprehensively trained eye specialists, bringing over two decades of focused clinical experience to her role as Additional Director of Ophthalmology at Fortis Memorial Research Institute, Gurgaon. She is a fellowship-trained Oculoplasty Surgeon, Neuro-ophthalmologist, and Ocular Oncologist — a rare combination that allows her to manage some of the most complex conditions affecting the eye, orbit, and surrounding… Read more
Dr. Nishchint Jain
DM, MD, DNB
Interventional Neuroradiologist
Fortis Hospital, Shalimar Bagh, New Delhi, India
10+ Yearsof experience
Dr. Nishchint Jain is a highly skilled Consultant in Interventional Neuroradiology practising at Fortis Hospital, Shalimar Bagh, New Delhi. He holds a DM (Interventional Neuroradiology) from the All India Institute of Medical Sciences (AIIMS), New Delhi, complemented by an MD and DNB qualification, with over 10 years of dedicated experience in neurovascular intervention. His training at one of India's most prestigious medical institutions has prepared him… Read more
Dr. Anuvrat Sinha
MBBS (with Distinction in Pharmacology), MS (General Surgery), MCh (Neurosurgery)
Neurosurgeon
Artemis Hospital, Gurugram, India
12+ Yearsof experience
Dr. Anuvrat Sinha is a Consultant Neurosurgeon at Artemis Hospital, Gurugram, with over 12 years of medical experience. He specialises in complex brain tumor surgeries — including glioma and meningioma — as well as endoscopic brain procedures, craniotomies, and a wide range of spinal surgeries. Patients and families often describe him as someone who takes the time to explain a difficult diagnosis in plain language, which matters enormously when the stakes… Read more
Dr. Arul K
MBBS, MS, FRCS (Ed) — Fellow of the Royal College of Surgeons of Edinburgh, Neurosurgery Board Certification
Neurosurgeon
Gleneagles HealthCity Chennai, Chennai, India
27+ Yearsof experience
Dr. Arul K is a seasoned neurosurgeon based in Chennai with over 27 years of experience caring for patients with complex brain and spine conditions. Currently serving as Associate Consultant at Gleneagles HealthCity Chennai, he has built a reputation for handling some of the most challenging neurosurgical cases — from skull base tumours and arteriovenous malformations to delicate endoscopic brain procedures. His patients and their families often describe… Read more
Dr. Deepak Arisikere Nataraju
MBBS, MS (General Surgery), M.Ch (Neurosurgery)
Neurosurgeon
Medicover Hospital, Whitefield, Bengaluru, India
20+ Yearsof experience
Dr. Deepak Arisikere Nataraju is a Senior Consultant Neurosurgeon at Medicover Hospitals, Whitefield, Bengaluru, with over two decades of experience in treating complex conditions of the brain, spine, and nervous system. He is widely recognized in the region for his work in minimally invasive spine surgery, endoscopic brain surgery, and skull base procedures — areas where precision and experience make a real difference to patient outcomes. Dr. Deepak… Read more
Frequently Asked Questions — Brain Cancer Treatment
The cost of brain cancer treatment in India typically ranges from $6,000 to $25,000 USD for the primary intervention (craniotomy or stereotactic radiosurgery) including hospital stay, neurosurgical fees, theatre charges, standard medications, and ICU/HDU monitoring. At JCI- and NABH-accredited hospitals in cities such as Chennai, Hyderabad, Mumbai, and Delhi, India delivers world-class neurosurgical outcomes at 50–65% lower cost than equivalent care in the UAE or Western countries. In the UAE (Dubai and Abu Dhabi), the same treatment range costs between $15,000 and $55,000 USD at JCI-accredited and DHA/DOH-licensed institutions such as Cleveland Clinic Abu Dhabi, Burjeel Medical City, and Mediclinic City Hospital Dubai. These estimates cover the primary surgical episode and standard inpatient stay. Multi-cycle adjuvant chemotherapy (e.g., 6 cycles of temozolomide at $500–$2,500 USD per cycle in India), proton beam therapy (approximately $20,000–$40,000 USD per course), and extended inpatient rehabilitation are priced separately and are always itemised transparently by GAF Healthcare in the pre-departure cost estimate.
The minimum safe in-country stay before international air travel is cleared depends on the type of brain cancer treatment received. For patients who undergo a craniotomy (open brain surgery), the treating neurosurgeon will typically clear the patient to fly internationally no earlier than 4–6 weeks after surgery. This timeframe allows adequate wound healing, resolution of perioperative cerebral edema, normalization of intracranial pressure, stable neurological recovery, and a post-operative MRI to confirm the absence of surgical complications. Patients with a high risk of deep vein thrombosis (DVT) or pulmonary embolism — which are elevated in neuro-oncology patients — require anticoagulation management and DVT exclusion before long-haul flights. For patients treated with stereotactic radiosurgery (Gamma Knife or CyberKnife) for brain metastases or small tumors, fitness to fly is typically assessed at 1–2 weeks after the procedure, pending neurological stability and the treating radiation oncologist's review. For patients who begin a 6-week (30-fraction) course of adjuvant radiotherapy in-country, the total stay will extend to approximately 8–10 weeks. GAF Healthcare ensures that the formal fitness-to-fly certificate is issued by the treating neurosurgeon or oncologist and that in-flight medical documentation, medication packs, and wheelchair assistance (where needed) are arranged prior to departure.
Success rates in brain cancer treatment vary substantially by tumor type, WHO grade, molecular profile, surgical resectability, and patient performance status, and must be understood in that context. For surgically resectable low-grade gliomas (WHO Grade II, IDH-mutant) and benign meningiomas (Grade I), gross total resection achieves 5-year progression-free survival rates of 80–92%, and 10-year overall survival exceeding 70–80%. Anaplastic gliomas (Grade III, IDH-mutant with 1p/19q codeletion — oligodendroglioma) treated with surgery plus PCV chemotherapy and radiotherapy show median overall survival exceeding 14 years in recent randomized trials. For glioblastoma multiforme (GBM, WHO Grade IV) — the most common and aggressive primary brain tumor in adults — the Stupp protocol (concurrent temozolomide + radiotherapy followed by adjuvant temozolomide) yields a median overall survival of 14–16 months, with approximately 5–10% of patients surviving 5 years; MGMT promoter-methylated GBM patients fare significantly better (median OS ~21–23 months). The addition of Tumor Treating Fields (Optune) to temozolomide extended median OS to 20.9 months versus 16 months in the landmark EF-14 Phase III trial. For brain metastases treated with stereotactic radiosurgery (SRS), local tumor control rates at 1 year exceed 85–90%. Pituitary adenomas treated endoscopically achieve remission in 70–90% of functioning tumors. GAF Healthcare's partner hospitals report gross total resection rates of 70–85% for operable tumors, consistent with international benchmarks at JCI-accredited high-volume neuro-oncology centers.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive end-to-end non-medical support to ensure that international patients and their families can focus entirely on treatment and recovery.
**For Treatment in India:**
• **e-Medical Visa (e-MV)**: GAF Healthcare's visa facilitation team guides patients through the Indian e-Medical Visa application (available from 170+ countries), which allows a triple-entry, 60-day stay extendable up to one year for ongoing treatment. Patients must provide the hospital appointment letter, which GAF secures from the partner hospital. Processing time is typically 2–5 business days. One e-MV companion visa is available for each accompanying attendant.
• **Hospitals**: Apollo Hospitals (Hyderabad, Chennai, Delhi), Fortis Memorial Research Institute (Gurugram), NIMHANS (Bangalore), Max Super Speciality Hospital, Kokilaben Dhirubhai Ambani Hospital (Mumbai) — all JCI- and/or NABH-accredited with dedicated International Patient Departments.
**For Treatment in the UAE (Dubai / Abu Dhabi):**
• **Visa**: Citizens of 50+ countries, including UK, EU, US, Canada, and Australia, receive visa-free or visa-on-arrival access to the UAE (30–90 days). For other nationalities, GAF facilitates medical visa or treatment visitor visa applications through the ICA (Federal Authority for Identity and Citizenship). UAE partner hospitals (Cleveland Clinic Abu Dhabi, Burjeel Medical City, Mediclinic City Hospital Dubai, American Hospital Dubai) are JCI-accredited and DHA/DOH-licensed with dedicated international liaison offices.
**All Destinations — Full-Service Support:**
• **Airport Transfers**: Private air-conditioned vehicle (wheelchair-accessible on request) for all airport-to-hospital and hospital-to-accommodation transfers, coordinated 24/7.
• **Dedicated Patient Coordinator**: A single point of contact at GAF Healthcare assigned to each patient for the duration of the journey — available via WhatsApp, email, and phone, bridging communication between the patient and the clinical team.
• **Language Interpretation**: Professional medical interpreters available for Arabic, Russian, French, Swahili, Bengali, and other major languages; on-site during all clinical consultations, surgical consent procedures, and MDT discussions.
• **Attendant Accommodation**: GAF arranges serviced apartments, guesthouses, or hotel rooms adjacent to or within walking distance of partner hospitals at negotiated rates for the patient's accompanying family members.
• **In-Hospital Concierge**: Assistance with appointment scheduling, pharmacy procurement, medical equipment rental (wheelchair, walker), SIM card, and currency exchange.
• **Telehealth Follow-Up**: Post-departure, GAF facilitates ongoing teleconsultation between the patient's home oncologist and the treating neuro-oncology team for continuity of adjuvant chemotherapy management, MRI surveillance review, and treatment response monitoring.
• **Medical Records Package**: All surgical reports, pathology, molecular genomics, radiology CDs, radiotherapy dosimetry files, and discharge summaries compiled, digitised, and shared via secure patient portal within 48 hours of discharge.
Patients Also Explore
Other treatments commonly sought by patients considering Brain Cancer Treatment.
Cryosurgery
Surgical Oncology
Robotic Surgery
Surgical Oncology
Anemia
Hematology
Leukemia Treatment
Hematology